Comparison of the effectiveness, safety, and costs of anti-Parkinson drugs: A multiple-center retrospective study.

CNS Neurosci Ther · 2024 · PMC11017413 · PMID 37983933

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

of borderline significancep = 0.07so close (0.05 < p ≤ 0.1)

33 Consistently, the increase in the overall incidence of side effects was generally more marked with dopamine agonists (OR 1.52) than with MAOBIs (OR 1.32), although heterogeneity between drug classes was only of borderline significance ( p = 0.07). 14 PD is the fourth most costly neurological disease after migraine, stroke, and epilepsy.

also in 446 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.